Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Liabilities and Shareholders Equity: 2011-2017

Historic Liabilities and Shareholders Equity for Tenax Therapeutics (TENX) over the last 4 years, with Sep 2017 value amounting to $11.0 million.

  • Tenax Therapeutics' Liabilities and Shareholders Equity fell 81.57% to $11.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $66.9 million, marking a year-over-year decrease of 66.53%. This contributed to the annual value of $23.3 million for FY2016, which is N/A change from last year.
  • Per Tenax Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $11.0 million for Q3 2017, which was down 18.19% from $13.4 million recorded in Q2 2017.
  • In the past 5 years, Tenax Therapeutics' Liabilities and Shareholders Equity registered a high of $73.0 million during Q4 2015, and its lowest value of $3.0 million during Q1 2013.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $23.3 million (2016), whereas its average is $37.7 million.
  • Data for Tenax Therapeutics' Liabilities and Shareholders Equity shows a maximum YoY tumbled of 81.57% (in 2017) over the last 5 years.
  • Quarterly analysis of 4 years shows Tenax Therapeutics' Liabilities and Shareholders Equity stood at $3.2 million in 2013, then reached $73.0 million in 2015, then crashed by 68.02% to $23.3 million in 2016, then plummeted by 81.57% to $11.0 million in 2017.
  • Its Liabilities and Shareholders Equity stands at $11.0 million for Q3 2017, versus $13.4 million for Q2 2017 and $19.2 million for Q1 2017.